ESTRO 2023 - Abstract Book

S1289

Digital Posters

ESTRO 2023

79%), DSS was 89%, and local recurrence-free survival was 89%. All patients with T1-2 tumors retained their eye, while eye preservation was 73% at two years for T3-4, mostly because of retinal detachment. Severe visual impairment was 58% at two years. 32 (57.1%) and 21 (37.5%) patients had Grade III and IV toxicity respectively (Table 1).

Conclusion Proton Therapy for ocular melanoma in The Netherlands is the treatment of choice when brachytherapy treatment is not feasible anymore. The treatment results in ocular preservation in the majority of the cases.

PO-1588 Palliative care assessment in glioblastoma multiforme treated in a radiotherapy department.

B. Deben Mendez 1 , M. Rodriguez Roldan 2 , M.I. Garrido Botella 1 , E. Gonzalez Del Portillo 1 , A.A. Ocanto Martinez 3 , M. Gonzalez Cantero 1 , M. Teja Ubach 1 , R. Rosel Aller 1 , D. Martinez Perez 4 , J. Pedregosa Barbas 4 , J.A. Garcia Cuesta 4 , C. García Torres 5 , A. Castaño Cantos 1 , Y. Vilches Aguirre 6 , A. Alonso Babaro 6 , R.M. Morera Lopez 2 1 Hospital Universitario La Paz, Radiation oncology department, Madrid, Spain; 2 Hospital universitario La Paz, Radiation oncology department, Madrid, Spain; 3 Hospital Universitario de Torrejón, Radiation oncology department, Madrid, Spain; 4 Hospital Universitario La Paz, Medical oncology department, Madrid, Spain; 5 Hospital Universitario Rey Juan Carlos, Radiation oncology department, Madrid, Spain; 6 Hospital Universitario La Paz, Palliative care department, Madrid, Spain Purpose or Objective Glioblastoma multiforme (GBM) is an infiltrating astrocytic tumor with a poor prognosis and a median survival of 12 months. Its standard treatment consists of maximal resection followed by STUPP (concomitant radiotherapy (RT) and temozolamide (TMZ) and 6 cycles of subsequent TMZ). The aim of this study was to report the proportion of patients who completed the full treatment regimen, and the proportion who were referred to palliative care (PC). Materials and Methods Retrospective descriptive study. Sample of 144 patients evaluated in a radiotherapy oncology service in a tertiary hospital diagnosed with high-grade glioma treated with RT from January 2016 to December 2019. We analysed clinical variables and possible prognostic factors for survival: whether patients completed the STUPP scheme, whether they completed RT treatment, whether they were assessed for PC and the median time between PC assessment and exitus. Results Among the 144 patients, 31 (21.5%) completed this standard treatment. RT treatment was completed by 92.4%. 66.7% of patients were assessed by a PC unit, with a median survival time between assessment and exitus of 1.68 months. Referral to PC was statistically significant as a prognostic factor for poorer survival (p<0.004). Conclusion This study indicates that patients with GBM complete a high percentage of RT treatment. However, few are referred to PC, with this referral being a prognostic factor for poorer survival, probably due to the funcional deterioration that occurs when this is done late. It is worth investigating whether earlier referral to PC would lead to a better prognosis.